Quantcast Omrix’s Biosurgical Products
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Omrix’s Biosurgical Products

Posted on 04/30/2007 08:25:52 | Link | Post Comment
by Brian Orelli
Baby Biotechs



Now I’m no surgeon, but I can guess that during surgery, there’s a lot of blood (actually, come to think of it, that’s part of the reason that I’m not a MD). Generally speaking, bleeding isn’t a good thing; Omrix’s (OMRI) biosurgical products and pipeline are designed to stop the bleeding (herein referred to by it’s clinical name, hemostasis).

Now how do you promote hemostasis in surgery? Well, the same way you do if you cut yourself when you’re shaving:

1. If it’s a small cut, you let the proteins in the blood form a clot (scab). Essentially fibrinogen, a protein in the blood stream, combines with another protein in the blood stream, thrombin, to form a clot. Omrix’s Evicel (marketed as Quixil outside the U.S.) is essentially purified fibrinogen. Since it’s purified from human plasma, it contains naturally occurring proteins as part of its biological active component (BAC), which help form a clot that sticks to the wound better. Omrix is also in phase 3 trials for purified thrombin, the other component of the clot, which results in a much slower hemostasis (preferred in some types of surgery).
2. If the cut is a little bigger or won’t stop on its own, you put a bandage on it. Omrix has designed a biodegradable patch that contains purified fibrinogen. The patch, which is in phase 1 clinical trials, is designed for high bleeding situations, like the emergency room, where the high flow/pressure from a wound rips a fibrinogen induced clot right off.


From my reading, it looks like they don’t have a patent on fibrinogen. Although they may have a patent on their purification process. Since they’re in a highly competitive field, they need to give the doctors a reason to buy their brand over any others. Omrix’s main advantage is that they purify fibrinogen out of human plasma while other competitors purify it out of cows, potentially causing the immune system to have to work overtime to fight off the perceived foreign infection. They’ve also packaged the fibrinogen in an easy to use form that can be stored at 4 degrees Celsius (refrigerator) for extended periods of time resulting in reduced waste of the product.

Omrix’s other competitive advantage in that they are good at purifying proteins out of human plasma. This same type of purification is used to create their passive imunotherapy product line, which I will talk about next time.


Source: BabyBiotechs.com

____________________
Stock Quote or
Examples
Editorial Spotlight - Tue Aug 19, 2008 05:27PM
College, they say, provides the best return of any inves [read more]
Morpheus Trading - Tue Aug 19, 2008 02:19AM
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Wed Aug 20, 2008 02:40AM
NOTE: Please click on the charts below to enlarge them if [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.